Slower ramp-up of new beds impacting margins
The large bed addition plan (~1,000 beds) may face ramp-up delays, with Manesar already incurring an EBITDA loss of INR 12 crore in Q4.
medium · management_commentary
Fortis Healthcare Limited — Q4 FY25
Fortis Healthcare reported a strong Q4 FY25 with consolidated revenue of INR 2,007 crore (+12.5% YoY) and EBITDA margin of 21.7% (+40bps YoY).
bullish
high
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Legal and legacy costs persist
Legal and other legacy costs continue to consume ~1% of EBITDA, with no near-term resolution expected for the Delhi High Court case.
medium · management_commentaryDiagnostic revenue growth may lag expectations
Despite margin improvement, Agilus revenue growth has been low single-digit; management's double-digit growth target may be challenged by competitive pressures.
medium · analyst_questionGeopolitical risks to international patient revenue
International patient revenue growth of 17% may not sustain due to geopolitical tensions, though management expects stable contribution.
low · management_commentary